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ABSTRACT: Ubiquinone or Co Q10 is essentially a vitamin like substance and is a cofactor of 
an enzyme.  It is an integral part of the memberanes of mitocondria where it is involved in the 
energy production.  It is a nutrient necessary for the function of every cell of the body especially 
vital organs of the body like heart, liver, brain etc.  Studies have shown that coenzyme Q10 alters 
the natural history of cardiovascular illness and has the potential of prevention of 
cardiovascular diseases through the inhibition of LDL cholesterol oxidation by maintenance of 
optimal cellular and mitochondrial function throughout the ravages of time internal and external 
stress. 
 
INTRODUCTION  
 
Ubiquinone is found in most body tissues, 
the highest amount is found in the heart, 
liver Kidney pancreas and lungs.  It is an 
integral part of the membrance of the 
mitochondria. Ubiquinone is vitamin like 
substance (simlar to vitamin A and E) and is 
coenzyme for at least three mitochondrial 
enzyme (complex I,II,III ) involved in 
oxidative phosphorylation  for the other part 
of the cell. Its electron and proton transfer 
function is of importance in electron 
transport side chain.
1-7 
 
Co Q is the nutrient necessary for the 
function of every cell of our body, without 
Co Q the food we eat cannot be converted to 
energy or it can be said that Co Q is 
especially related with energy production in 
cell with high metabolic demand.  Apart 
from this main function, it also serves as an 
efficient antioxidant. 
8-11. 
 
Upiquinone is only lipid soluble coenzyme 
of mitochondria and can migrate freely in 
the lipid mass of the mitochondria and can 
easily accept electron and protons from 
various dehydrogenase system with the 
reversible formation  of dehydroubiquinone 
thus is get reduced and can  oxidized other 
biomolecules.  The  reduced and can 
dehydroubiquinone can undergo oxidation 
and reconverted to oxidized form i.e. 
ubiquinone  by cytochrome b and like 
substances in the body and further 
propagates the electron transport chain. 
12 
 
The energy released during various stages of 
this redox system is conserved in the 
presence of ADP and inorganic Phosphate 
resulting in the formation of ATP, whish can 
be utilized for several metabolic needs thus 
making it essential for ht survival of living 
beings. 
 
CHEMISTRY: 
 
Chemically ubiquinone has a quinoid   
structure, one at 2
nd  and one at 3
rd position, 
a methy1 group at 5
th  position and a 
isoprenoid side chain at 6
th position of 
quinoid ring.  The number of isoprenoid nuit 
in the side chain varies from 6-10 for Co 
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Q10, the number is 10.  The physiologically 
active form has all Trans configuration. 
13,14. 
 
CLINICAL INDICATION : 
 
The usefulness of ConQ10 in heart diseases is 
slowly but steadily been established in the 
past 30 years, after the discovery of Co Q10 
by frederick crane et al. in 1957,others 
investigators and its first use in heart failure 
15-17 
Co Q10 is know to be highly concentrated in 
heart muscle cells, as cardiac cells have high 
metabolic demands in term of energy and 
Co Q 10 is associated with energy 
production. Co Q10 has received particular 
attention in the prevention and treatment of 
various cardiovascular diseases like 
congestive heart failure, hypertension, 
arthymia’s ischemia, reperfusion injury and 
to hasten post cardiac surgery recovery. 
 
HYPERTENSION: 
 
Hypertension has always been associated 
with cardiac complications or development 
of other cardiac problems, studies have 
provided evidences that Co Q10 
supplementation reduces blood levels of 
epinephrine (Adr) and other catecholamines.  
This is stated to be responsible of reduction 
of blood pressure and it protects the vascular 
endothelium from free radical induced 
damages.  The property of reducing number 
of platelets and its size is also helpful in the 
management of hypertension. 
18-20. 
 
CONGESTIVE HEART FAILURE: 
 
The efficacy and safety of Co Q 10 in the 
treatment of CHF, whether related to 
primary cardiomyopathies or secondary 
forms of heart fail appears to be well 
established. 
21, 22. 
 
Co Q 10 treatment in CHF revealed a 
significant important cardiac parameters 
such as ejection fraction, stroke volume, 
cardiac output cardiac index and end 
diastolic volume index
 23. 
 
DIASTOLIC DYSFUNCTIONNING: 
 
Use of Co Q 10 improves diastolic function 
in all categories of cardiac disease and this 
improvement occurs earlier and is more 
consistent than improvement is systolic 
function.  Diastolic dysfunction often 
precedes more advanced stages of 
congestive heart failure and is commonly 
seen in a wide variety of clinical syndromes, 
including symptomatic  hypertensive heart 
diease with left ventricular hypertrophy , 
symptomatic mitral prolapse, hypertropic 
cardiomyopathy, aging heart etc. and often 
seen in fatigue status such as chronic fatigue 
syndromes. 24 Co Q 10  has shown 
improvement in diastolic function, a 
decrease in myocardial thickness and also 
improvement in functional classification, 
Load induced diastolic dysfunction is also 
normalized by CoQ10 supplementation, is 
also causes lessening in hypertrophy and 
improvement. In functional status of patients 
with hypertropic cardiomyopathy with 
overall improvement in diastolic function. 
25 Co Q10  supplementation no only causes 
improvement in NYHA classification and 
left ventricular hypertrophy but a significant 
improvement in diastolic function of 
hypertensive heart patients and also of that 
associated with aging heart 
26,27. 
ISCHEMIC HEART DISEASES: 
 
Study have shown that Co Q 10 
supplementation in chronic stable anginal 
patients improves myocardial function 
measurements, improves exercise capacity, 
significant reduction in the number of 
anginal episodes and nitrate consumption. 
Since the Co Q10  treatment causes no 
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significant alteration in heart rate or blood 
pressure thus indication that the mechanism 
of action is directly related to myocardial 
metabolism 28 30 Co Q 10  related to 
frequency of angina attack.  Study has 
proved that Co Q 10 reduces frequency of 
angina attack up to 46% while improving 
the capacity of physical activity for those 
patients
31. 
 
OXIDATION (LDL CHOLESTEROL) 
 
: it is generally believed that the oxidation of 
LDL cholesterol is of primary importance in 
the development of artersclerosis.   
Supplementation of Co Q 10  prevents the 
oxidant effect of alpha tocopherols 
32. 
Supplementation with vitamin E alone 
results in LDL, which was more prone to 
oxidation. Supplementation of Co Q10 and 
vitamin E which increases the resistance to 
oxidation, Supplementation of Co Q10 
increases the amount of Co Q 10  and 
lowered the peroxidiazibility of the LDL. 
33-
34. 
 
PRE AND POST OPERATIVE 
RECOVERY:  
 
Preoperative Co Q10 administration in 
patients undergoing heart valve replacement 
has significantly reduced the incidence of 
low cardiac output state during post 
operative recovery period
35.  Administration 
of Co Q 10 prior to coronary artery bypass 
graft, cardiopulmonary by pass surgery, has 
shown a significant improvement of left 
ventricular stroke work index 
postoperatively 
36. In patients undergoing 
coronary artery by pass surgery with valve 
replacement , a pre-operative Co Q 10 
administration has shown significant 
improvement in post operative cardiac index 
an left ventricular ejection fraction with a 
significant reduction in post –operative 
recovery time and also significant decrease 
in postoperative markers of oxidative 
damage.  A low in cadence of ventricular 
arrhythmia is also seen during recover 
period 
32, 38. 
 
The same improvement was observed with 
CoQ10 supplementation in left atrial pressure 
and low cardiac output state during 
postoperative period and a right and left 
ventricular myocardial ultrastructure was 
better prevented. 
 
A significant decrease in markers of 
peroxidative damage was observed in Co 
Q10 treated patients
40. 
 
CoQ10 protects the myocardium form 
ischemic reperfusion injury by its ability to 
increase aerobic energy production, protects 
creatine kinase form oxidative inactivation 
as well as its activity as an antioxidant 
41-43. 
 
Improved cardiovascular morbidity and 
mortality have been observed in several 
clinical studies of dietary supplementation 
with Co Q10 One attraction theory links Co 
Q10  with the inhibition of Platelets, 
Significant inhibition of vitronectin receptor 
is a direct evidence of link between dietary 
Co Q 10 intake, platelets and homeostasis
44 
 
CANCER AND OTHER DISEASES:  
 
Apart from the benefits in various   
cardiovascular diseases Co Q 10  also shown 
light of hope in the treatment of cancer,   
neurogenerative diseases and problems 
associated with weight gain. 
Preliminary evidences suggests that Co Q10 
may suppress the proliferation of cancer 
cells and boost factor that kill cancer cells.  
Even a suppress the proliferation of cancer 
cells and boost factor that kill cancer cells.  
Even a spontaneous regression of breast 
cancer has been observed in some patients.  
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CoQ10 deficiency was noted in both 
carcinomas and non-malignant lesions 
45 46. 
 
Studies have shown that the administration 
of Co Q 10 resulted in significant increase in 
cerebral cortex mitochondrial concentration 
of Co Q 10 Oral administration of Co Q 10 
markedly attributed striatal lesions produced 
by systemic administration of 3 nitro 
propionic acid and significantly increased 
life span.  These results shows that oral 
administration of Co Q10 increases both 
brain and brain mitochondrial concentrations 
Co Q10 can exert neuro protective action. Co 
Q10 can attenuate the MPTP induced loss of 
striatal dopamine and dopaminergic axon in 
aged mice and suggests that Co Q10 may be 
useful in the treatment of Parkinson’s 
disease. Studies indicate that oral   
administration of Co Q 10 significantly 
reduces increased concentration of lactate in 
the occipital cortex of Huntington’s disease 
patients. These findings suggest that Co Q10 
may be useful in treating neuro degenerative 
disease
47. various studies have shown that 
obese peoples are always deficient in Co Q10 
levels (50%) and like people can lose weight 
simple with the addition of Co Q 10 This 
enzyme increases metabolic fuel efficiency 
within the cell thereby stimulate the natural 
weight loss
48. 
 
CONCLSION:  
 
Thus it can be concluded that coenzyme Q10 
through a simple molecule but it’s a 
essential requirement for the survival of 
human beings, Being involved in almost all 
energy related metabolic processes, Co Q10 
supplementation has proved a beneficial 
effect in several metabolic disorders, most 
common among them are related with 
cardiovascular system.  Apart from the 
beneficial effect in congestive heart failure, 
it has proved to be equally effective in 
ischemic heart diseases, hypertension and 
diastolic dysfunctioning, it has been also 
found to improve the postoperative recovery 
in several cardiac  surgeries.  
 
Besides these, studies are showing evidences 
for its effect in carcinomas, Parkinsonism 
and problems associated with weight gain.   
Hence further attention should be provided 
on this essential coenzyme Q10, as the best 
preventive measure from several severe 
diseases. 
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